| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Basic and Clinical Myology Laboratory, Department of Physiology, The University of Melbourne, Victoria, Australia
Submitted 10 April 2006 ; accepted in final form 12 April 2006
The absence of dystrophin and resultant disruption of the dystrophin glycoprotein complex renders skeletal muscles of dystrophic patients and dystrophic mdx mice susceptible to contraction-induced injury. Strategies to reduce contraction-induced injury are of critical importance, because this mode of damage contributes to the etiology of myofiber breakdown in the dystrophic pathology. Transgenic overexpression of insulin-like growth factor-I (IGF-I) causes myofiber hypertrophy, increases force production, and can improve the dystrophic pathology in mdx mice. In contrast, the predominant effect of continuous exogenous administration of IGF-I to mdx mice at a low dose (1.0–1.5 mg·kg–1·day–1) is a shift in muscle phenotype from fast glycolytic toward a more oxidative, fatigue-resistant, slow muscle without alterations in myofiber cross-sectional area, muscle mass, or maximum force-producing capacity. We found that exogenous administration of IGF-I to mdx mice increased myofiber succinate dehydrogenase activity, shifted the overall myosin heavy chain isoform composition toward a slower phenotype, and, most importantly, reduced contraction-induced damage in tibialis anterior muscles. The deficit in force-producing capacity after two damaging lengthening contractions was reduced significantly in tibialis anterior muscles of IGF-I-treated (53 ± 4%) compared with untreated mdx mice (70 ± 5%, P < 0.05). The results provide further evidence that IGF-I administration can enhance the functional properties of dystrophic skeletal muscle and, compared with results in transgenic mice or virus-mediated overexpression, highlight the disparities in different models of endocrine factor delivery.
insulin-like growth factor-I; fiber type; myosin heavy chain; muscular dystrophy
This article has been cited by other articles:
|
|
 |
|
  H. Vandenburgh, J. Shansky, F. Benesch-Lee, K. Skelly, J. M. Spinazzola, Y. Saponjian, and B. S. Tseng Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts FASEB J, October 1, 2009; 23(10): 3325 - 3334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Legate, S. A. Wickstrom, and R. Fassler Genetic and cell biological analysis of integrin outside-in signaling Genes & Dev., February 15, 2009; 23(4): 397 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Blaauw, C. Mammucari, L. Toniolo, L. Agatea, R. Abraham, M. Sandri, C. Reggiani, and S. Schiaffino Akt activation prevents the force drop induced by eccentric contractions in dystrophin-deficient skeletal muscle Hum. Mol. Genet., December 1, 2008; 17(23): 3686 - 3696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Gehrig, J. G. Ryall, J. D. Schertzer, and G. S. Lynch Insulin-like growth factor-I analogue protects muscles of dystrophic mdx mice from contraction-mediated damage Exp Physiol, November 1, 2008; 93(11): 1190 - 1198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Schertzer, C. v. d. Poel, T. Shavlakadze, M. D. Grounds, and G. S. Lynch Muscle-specific overexpression of IGF-I improves E-C coupling in skeletal muscle fibers from dystrophic mdx mice Am J Physiol Cell Physiol, January 1, 2008; 294(1): C161 - C168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Ryall, J. D. Schertzer, and G. S. Lynch Attenuation of Age-Related Muscle Wasting and Weakness in Rats After Formoterol Treatment: Therapeutic Implications for Sarcopenia J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2007; 62(8): 813 - 823. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
